Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more
Ocular Therapeutix Inc (OCUL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.083x
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has a cash flow conversion efficiency ratio of -0.083x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.25 Million) by net assets ($654.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ocular Therapeutix Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ocular Therapeutix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocular Therapeutix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Merchants Port Holdings Company Limited
PINK:CMHHF
|
0.034x |
|
Hang Lung Properties Limited
F:AOP
|
0.008x |
|
CTP N.V
PINK:CTPVF
|
0.018x |
|
Joinn Laboratories(China)Co
SHG:603127
|
0.018x |
|
Glodon Software Co Ltd
SHE:002410
|
0.069x |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
0.078x |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
0.022x |
|
Nicolet Bankshares Inc.
NYSE:NIC
|
0.036x |
Annual Cash Flow Conversion Efficiency for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocular Therapeutix Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $654.31 Million | $-204.88 Million | -0.313x | +26.68% |
| 2024-12-31 | $315.34 Million | $-134.68 Million | -0.427x | +44.58% |
| 2023-12-31 | $91.13 Million | $-70.23 Million | -0.771x | +54.25% |
| 2022-12-31 | $35.38 Million | $-59.60 Million | -1.685x | -126.17% |
| 2021-12-31 | $88.00 Million | $-65.55 Million | -0.745x | -5.84% |
| 2020-12-31 | $76.09 Million | $-53.55 Million | -0.704x | -103.29% |
| 2019-12-31 | $-3.63 Million | $-77.58 Million | 21.371x | +1657.47% |
| 2018-12-31 | $35.88 Million | $-49.23 Million | -1.372x | +28.92% |
| 2017-12-31 | $26.15 Million | $-50.47 Million | -1.930x | -195.27% |
| 2016-12-31 | $52.01 Million | $-34.00 Million | -0.654x | -73.58% |
| 2015-12-31 | $89.59 Million | $-33.74 Million | -0.377x | -7.86% |
| 2014-12-31 | $58.70 Million | $-20.50 Million | -0.349x | -264.23% |
| 2013-12-31 | $-59.47 Million | $-12.64 Million | 0.213x | -21.25% |
| 2012-12-31 | $-46.61 Million | $-12.59 Million | 0.270x | -- |